Ignite Creation Date:
2024-05-06 @ 5:45 PM
Last Modification Date:
2024-10-26 @ 2:34 PM
Study NCT ID:
NCT05411380
Status:
RECRUITING
Last Update Posted:
2022-11-04
First Post:
2022-06-05
Brief Title:
Tucidinostat Combined With Metronomic Capecitabine and Endocrine Therapy for Advanced HR-positive HER2-negative Breast Cancer After CDK46 Inhibitor
Sponsor:
wang shusen
Organization:
Sun Yat-sen University
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-10-03
Start Date Type:
ACTUAL
Primary Completion Date:
2024-04-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-04-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-06-05
First Submit QC Date:
June 5 2022
Study First Post Date:
2022-06-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-11-01
Last Update Post Date:
2022-11-04
Last Update Post Date Type:
ACTUAL